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CONNECTIVE TISSUE ACTIVATION 
XXVIII. A Connective Tissue Activating Peptide from Human Urine 
MICHAEL A. GORDON, MORLEY D. HOLLENBERG, and C. WILLIAM CASTOR 
A protein factor in human urine which has the 
ability to activate connective tissue cells has been identi- 
fied and partially purified; it appears to be different 
from epidermal growth factor and IgG. This urinary 
connective tissue activating factor (CTAP-U) is nondia- 
lyzable, labile to protease, stable to thiols, heat, and 
acid, and has an acidic isoelectric point. Purified prepa- 
rations of CTAP-U have biologic activities that cause 
human connective tissue cells to synthesize incremental 
amounts of 14C-hyaluronic acid, 35S-proteoglycans, and 
3H-DNA in vitro. The cell spectrum responsive to this 
substance includes human synovial cells, human chon- 
drocytes, and skin fibroblasts. CTAP-U does not react 
with antisera to connective tissue activating peptide-I11 
or to antibodies against IgG or its Fc and Fab frag- 
ments. Furthermore, CTAP-U does not cross-react in a 
radioreceptor assay for insulin, basic somatomedin, or 
epidermal growth factor-urogastrone. Utilizing stan- 
dardized isolation conditions, CTAP-U preparations 
with these properties have been isolated from the urine 
of 6 normal individuals. 
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Human connective tissue cells are “activated” 
in vitro when incubated with extracts of human plate- 
lets, lymphocytes, and polymorphonuclear leukocytes 
(PMN) (1-3). Activation consists of a constellation of 
metabolic events including: stimulation of glycosamin- 
oglycan (GAG) synthesis (both hyaluronic acid [HA] 
and sulfated GAG), increased glucose uptake, in- 
creased lactate production, and increased DNA syn- 
thesis. The activation process is mediated by peptides 
isolated from the cellular extracts and termed connec- 
tive tissue activating peptides (CTAPs). CTAP-I from 
lymphocytes, CTAP-111 and CTAP-P2 from platelets, 
and CTAP-PMN from polymorphonuclear leukocytes 
have been at least partially characterized (4-9). CTAP- 
111 has been sequenced (8), and antisera prepared in 
rabbits are available (10). 
Evidence exists that cell activators, or growth 
factors, are excreted into the urine in a biologically 
active form. Holley and Kiernam found that a partially 
purified factor from urine stimulated growth in cul- 
tured 3T3 fibroblasts ( I  l). Epidermal growth factor- 
urogastrone (EGF-URO) was isolated from human 
urine and its biologic activity verified (12-15). Among 
its numerous biologic effects, EGF-URO i s  mitogenic 
in various cell culture systems and may stimulate 
hyaluronic acid synthesis, glycolysis, and the uptake 
of sugars and amino acids (14). The gastric antisecre- 
tory hormone isolated from human urine by Gregory, 
P-urogastrone, has been shown to be the human 
equivalent of mouse epidermal growth factor (15); the 
combined term epidermal growth factor-urogastrone 
depicts the dual biologic activities that the peptide 
exhibits. 
The present report describes another biological- 
ly  active urinary protein fraction. These connective 
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tissue activating materials from urine (or CTAP-U) 
were found in the urine of 6 normal subjects. CTAP-U 
possesses biologic activities similar t o  the  C T A P  fam- 
ily of polypeptides isolated from other sources and 
appears to  be different from EGF-URO.  
MATERIALS AND METHODS 
CTAP-U isolation methods. Urine samples (24-48- 
hour), from normal subjects, were collected without preser- 
vatives and stored at 4°C. Within 12 hours of collection, 
specimens were passed through a Prefilter (Millipore, Bed- 
ford, MA) to remove cellular debris, concentrated with a 
Pellicon cassette system (Millipore) to approximately 125 
ml, and then dialyzed against 0.05MTris. 0. IM KCI, pH 7.0. 
by continuous volume dialysis. The concentrated prepara- 
tions were passed over a blue Sepharose CL-6B column (2.5 
x 10 cm, Pharmacia, Uppsala, Sweden) equilibrated with 
O.OSM Tris, 0.1M KCI at pH 7.0. The unbound fraction was 
concentrated using the Pellicon cassette system, at which 
time I of 2 isolation methods was used, as shown in Figure I .  
In method A ,  samples were dialyzed against a mix- 
ture of 14 simple amphoteric and nonamphoteric buffers 
(0.025M “standard buffer”) as described by Prestidge and 
Hearn (16). Preparative isoelectric focusing using the meth- 
od of Prestidge and Hearn was carried out for 20-46 hours 
using Sephadex (3-75 fine (Pharmacia). equilibrated with 
0.025M standard buffers. Fractions with isoelectric points 
between 3.8 and 4.4 were pooled, concentrated with CX-10 
immersible filters (Millipore), dialyzed against 1 .OM acetic 
acid, pH 2 . 2 5 ,  and fractionated with a Sephadex GI00 
column (2.5 x 25 cm). 
In method B ,  fractions were dialyzed against 0.05M 
citrate buffer, pH 3.0, then passed over a SP-Sephadex 
column (2.5 x 5 cm, Pharmacia). Fractions were eluted with 
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Figure 1. Outline of 2 isolation procedures yielding partially purified 
connective tissue activating materials from urine. IEF = isoelectric 
focusing. 
O.OSM citrate buffers, dialyzed against 0.1M NH4HCO3. 
lyophilized, and dialyzed against 0.15M NaCl in preparation 
for bioassay. 
Fibroblast culture methods. Normal synovial cell 
strains were developed from explants obtained during ampu- 
tation or arthrotomy as described previously (17). Cells were 
grown in T-75 flasks in medium consisting of 80% CMKL 
1066, 10% fetal calf serum (FCS), 10% human serum supple- 
mented with NaHC03. L-glutarnine, HEPES buffer, penicil- 
lin, streptomycin, gentamicin, and erythromycin. Human 
dermal cells were obtained from explants (17) and chondro- 
cytes by collagenase digestion of cartilage from human hip or 
knee surgery (18). 
Glycosaminoglycan assays. l h e  assay utilized mea- 
sures ‘‘C-gIucosamine incorporation into glycosaminogly- 
cans (19). In brief, cells were trypsinized, counted with an 
electronic cell counter (Coulter Electronics, Hialeah, FL). 
and placed in microtiter polystyrene culture plates (Costar, 
Cambridge, MA) at a density of 2 x lo4 cells/well per 0.1 ml 
of 99% Leibovitz- 15 medium (Pacific Biologicals, Berkeley, 
CA) and 1% FCS. After 24 hours at 37”C, 100 pl of I4C-D- 
glucosamine (specific activity 250 mCi/mM, New England 
Nuclear, Boston, MA) in 99% L-15. I% FCS (0.5 pCi/ml) 
was added. After addition of the isotope. 20 pI of CTAP-U in 
0.15M NaCl and control vehicles were added to the micro- 
cultures, and incubation continued at 37°C for 40 hours. 
One hundred microliters of medium was spotted on 
Whatmann 3 MM filter paper, dried. immersed in a solution 
of 0.1% cetylpyridinium chloride (CPC). and washed 8 times 
with 0.1N NaOH to remove unincorporated ‘‘C-glucos- 
amine. Isotope incorporation into GAGS was measured by 
liquid scintillation counting in a Beckman 7000 scintillation 
counter, using a toluene-POPOP-PPO system. All experi- 
mental groups were plated in quadruplicate and data were 
expressed as mean 5 1 standard deviation. 
Sulfated glycosaminoglycans were measured by de- 
termining l5SO4 incorporation into GAGS (5). Microcultures 
were handled as in the “C-glucosamine assay except that 
carrier-free l-’S04 (50 pCi/ml) was the radioactive precursor. 
The GAG from 100 pl of media was precipitated on What- 
mann 3 MM filter paper using 0.1% CPC solution. washed 4 
times with 0.3M NaCl and 0.1% CPC, and counted in a 
Beckman 7000 scintillation counter. 
Qualitative determination of the GAG types was 
accomplished by incubating 50 pI of media or control 
materials with fungal hyaluronidase, 50 TRU/ml (ex. Strep- 
tomyces hyalurolyticus) in 0.15M Na acetate, pH 5, chon- 
droitinase ABC (2.5 unitslml) in 0.2M Tris, pH 7.5, and 
chondroitinase AC (2.5 unitdml) in 0.2MTris, pH 7.5 for 150 
minutes at 3 7 T ,  then subjecting the digested samples to the 
CPC-fixation wash procedure (19). 
Chondrocyte proteoglycan monomer production. One 
million human chondrocytes in the eighth passage were 
incubated in T-25 flasks in 3.2 ml of 97% Eagles’s synthetic 
medium (ESM), 3% FCS for 5 days. Then 0.3 ml of semipuri- 
fied CTAP-U (835 pg/ml) or control vehicle was added along 
with ”SO4 (100 pCi/ml, Amersham, England) and incuba- 
tion continued for 48 hours at 37°C. l‘he supernatant medium 
was removed, dialyzed against phosphate buffered saline 
(PBS), lyophilized, and redissolved in 1.5 ml of 0.5M Na 
acetate, pH 6.9. A 0.5-ml aliquot was subjected to gel 
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Figure 2. Preparative isoelectric focusing of urinary proteins not 
bound to blue Sepharose CL-6B. CTAP-C = connective tissue 
activating material from urine. 
filtration on Sepharose 4B (1.5 x 16 cm) and Sepharose'2B 
(1.5 x 16 cm). The eluate was spotted on filter paper, dried, 
and counted in a scintillation counter. 
Measurement of mitogenic activity. The rate of DNA 
synthesis by human synovial cells as measured by 'H- 
methylthymidine incorporation has been previously de- 
scribed (4). Cells ( 1  x 104/well) were plated in microtiter 
wells (Costar) in 100 p1 of 97% ESM and 3% FCS. After 24 
hours at 37"C, 5 pl of CTAP-U or control material was added 
and incubated for 24 hours at 37°C. Fifteen microliters of 'H- 
methylthymidine (1.5 pCi/well) in 100% ESM was added. 
After 24 hours, the incubation medium was discarded and 
the cell sheet was washed twice with PBS, 5% trichloroacetic 
acid, and 100% methanol and then allowed to dry. Following 
cell lysis with 50 pl of 0.3N NaOH, extracts were spotted on 
glass filter paper and counted in a Beckman 7000 liquid 
scintillation counter. 
Other procedures. Polyacrylamide gel electrophore- 
sis was performed using 15% gels in sodium dodecyl sulfate 
(SDS) and glycine-Tris buffers (20). Proteins were measured 
by a spectrophotometric method (21). Double immunodiffu- 
sion was performed using the Ouchterlony method. Mouse 
EGF (100 pg/ml) was purchased from either Collaborative 
Kesearch (Waltham, MA) or ICN (Cleveland, OH) or was 
isolated from mouse submaxillary glands according to the 
method of Savage and Cohen (22). A sample of P-urogas- 
trone was kindly provided by Dr. H. Gregory, Cheshire, 
UK. Rabbit anti-human IgG, goat anti-human Fc, and Fab 
fragments of IgG were purchased from Miles, Yeda, Israel. 
Anti-mouse EGF antisera (B/Bo = 0.35 at 1/18,000 dilution 
of antiserum) were raised in rabbits, using mouse EGF- 
URO, prepared according to the method of Savage and 
Cohen (22). This antiserum (MDH-150) cross-reacted weak- 
ly with human EGF-URO (B/Bo = 0.35 at a dilution of 1/300 
of antiserum). 
The radioreceptor assays (KRA) for epidermal 
growth factor, basic somatomedin (equivalent to somatome- 
din-C or insulin-like growth factor-I [23,24]), and for insulin 
were performed essentially as previously described (25). 
Antiserum and radiolabeled basic somatomedin were kindly 
provided by Drs. B. Bhaumuck and R. M .  Bala, Department 
of Medicine, University of Saskatchewan, Saskatoon, Can- 
ada. Antibody to CI'AP-111 was raised in rabbits as previous- 
ly described (10). 
RESULTS 
Isolation of CTAP-U. Urine specimens from 6 
normal subjects were studied separately for their 
CTAP-U activity. A Pellicon cassette system with a 
molecular weight cutoff of 10,000 daltons concentrated 
and dialyzed 48-hour collections to a volume of 100 ml 
in 2-3 hours. In 15 experiments these crude concen- 
trates stimulated ''C-glucosarnine incorporation into 
GAG at rates 1.6 to 7.0 times that of control; in 9 
experiments the concentrates enhanced tritiated thy- 
midine incorporation into DNA at rates 1.3 to 5.2 
times control rates. 
Albumin, a major contaminating protein, was 
removed without significant loss of biologic activity by 
passage over a blue Sepharose CL-6B column. The 
albumin-free unbound fraction was then fractionated 
Table 1. Partial purification of connective tissue activating material from urine 
Acpm in 
'T-gl  ycosaminogl ycan Specific 
Total fraction Protein (mg) assay' activityt 
~ 
Unbound fraction from 41.5 
blue Sepharose 
CL-6B 
pH 4.0 fraction from 6.8 










* Acpm refers to difference in ''C-hyaluronic acid (cpm/100 pI media) between test and vehicle treated 
assay wells. 
t Specific activity = Acpmigg protein in assay wells. 
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Table 2. Characteristics of connective tissue activating material 
from urine (CTAP-U) 
Fraction 
cpm. 'T- Experi- 
glycosami- mental: 
noglycan control* 
0. ISM NaCl 







CTAP-U + pronase 
CTAP-U t saline 
Pronase + saline 
1,203 2 180 
1,423 2 100 
3.661 2 293 
3,733 2 235 
4,617 ? 444 
4,058 2 317 
3,556 2 132 
1,055 5 108 
4,154 2 583 








0 .9  
* Ratio of cpm in experimental and control wells. See Materials and 
Methods for procedures used. 
by isoelectric focusing; typical running voltages start- 
ed near 170V and gradually increased to 1,100V over 
20-40 hours. Protein recovery from the gel bed was 
approximately 50%. 
Two major protein peaks were present, one at 
pH 2.3 and a second with a pH between 3.9 and 4.6 
(Figure 2). Fractions from the second peak showed a 
four- to eightfold increase in 14C-glucosamine incorpo- 
ration into GAG, compared with saline controls. 
These fractions were free of CTAP-111, human IgG, 
human Fc, and Fab fragments of IgG, as determined 
by double immunodiffusion. Subsequent isoelectric 
focusing experiments were carried out for 46 hours, 
and lactic and proprionic acids were added to the 
buffer mixture to enhance the acidic end of the gel bed. 
This provided a reproducible linear pH gradient be- 
tween 2.0 and 8.0. 14C-glucosamine incorporation into 
GAG was again stimulated by the large protein peak 
between pH 3.9 and 4.6. In addition, minor stimula- 
tory activity (experimental :control ratios 1.3-2.0) was 
present in fractions 12-26 (pH 5.1-7.7). These frac- 
tions formed precipitin lines with rabbit anti-human 
IgG and goat anti-human Fc and Fab fragments of IgG, 
but not with CTAP-111. 
The second peak (pH 3.9-4.6) was further 
fractionated with Sephadex G- 100 under dissociative 
conditions using 1 .OM acetic acid. Two fractions (Vc 
and Ve) eluting near cytochrome C (molecular weight 
12,384 daltons) yielded experimentakcontrol ratios of 
33.6 and 41.3, respectively ( P  < 0.001) in the I4C- 
glucosamine assay. One of these fractions (Ve) was 
tested for basic somatomedin content by radio- 
immunoassay (RIA) and radioreceptor assay; insulin 
content was measured by RRA. No reaction was 
detected in the basic somatomedin or insulin assays in 
which 2 pg of protein from fraction Ve was added to 
assays sensitive to 0.4-1 ng of either insulin or basic 
somatomedin. 
Since the isoelectric focusing experiments sug- 
gested that the PI of CTAP-U activity was between 3.9 
and 4.6, anion exchange experiments were performed 
using SP-Sephadex to fractionate material which did 
not bind to blue Sepharose. The unbound material was 
applied using 0.05M citrate buffer, pH 3.0, then eluted 
batchwise with increasing pH, using O.05M citrate 
buffers. Potent stimulators of GAG synthesis were 
eluted at pH 4.0 and 4.5. The specific activity, as 
defined in the 14C-glucosamine assay, was increased 
by this procedure (Table 1). Fractions eluting at pH 4.0 
and 4.5 did not react with antisera to CTAP-111, IgG, 
or Fc and Fab fragments of IgG. 
Polyacrylamide gel electrophoresis of the pH 
4.5 fraction using 15% gels in SDS buffer showed 2 
major bands at 35,000 daltons and 25,500 daltons, a 
minor band at 14,000, and 4 faint bands between 
50,000 and 78,000. The electrophoretic patterns for 
CTAP-U (pH 4.0 and 4.5 fractions) from 6 normal 









5 0 0 0  ~ 
4 0 0 0  - 
3000 ~ 
2 0 0 0 .  
1000 - 
G C  Caw EB DM 
INDIVIDUAL HUMAN SYNOVIAL CELL STRAINS 
Figure 3. Partially purified connective tissue activating material 
from urine (CTAP-U) stimulates ''C-hyaluronic acid (l4C-HA) syn- 
thesis in 4 different normal adult human synovial cell strains. 
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Figure 4. Partially purified connective tissue activating material 
from urine (CTAP-U) stimulates 3'S-glycosaminoglycan (GAG) syn- 
thesis by human synovial cultures. Stimulation by CTAP-U is less 
potent than that by CTAP-111. 
Characteristics of CTAP-U. CTAP-U, like the 
other CTAP mediators, was inactivated by protease 
digestion. One milliliter of pH 4.5 fraction (734 pglml) 
was incubated with either pronase (200 pg in 0.05M 
Tris, pH 7.9) or O.15M NaCl at 37°C for 4 hours, 
dialyzed against 0.15M NaCl overnight, and then 
tested in bioassay. As shown in Table 2, pronase 
completely abolished the GAG stimulatory activity of 
CTAP-U. Heating partially purified CTAP-U to 100°C 
for 10 minutes had no effect on incremental hyaluron- 
ate synthesis. Incubation of CTAP-U with either 
0.001M dithioerythritol and 0.15 NaCl at 4°C or 1% 2- 
mercaptoethanol, or 1M acetic acid (pH 2.25) for 24 
hours at 4"C, followed by dialysis against 0.15M NaCl 
for another 24 hours at 4"C, did not impair the I4C-HA 
stimulating capacity of CTAP-U. 
Effect of CTAP-U on GAG formation. CTAP-U 
was a potent stimulator of glycosaminoglycan forma- 
tion. In 10 synovial cell strains, CTAP-U at various 
stages of purification and at concentrations from I to 
830 pg/ml markedly stimulated the incorporation of 
''C-glucosamine into GAG. Experimenta1:control 
(E:C) ratios ranged from 2.3 to 10.0 with a mean of 5.1 
? 2.7 in different experiments. A representative ex- 
periment comparing the responses of 4 normal synovi- 
a1 cell strains is shown in Figure 3 .  Enzyme digestion 
of GAGs in the cell media show-ed that 78% was 
hydrolyzed by fungal hyaluronidase, while 81 % was 
hydrolyzed by both chondroitinase ABC and chon- 
droitinase AC. Thus, virtually all of the I4C-GAG 
produced by the synovial cells was hyaluronic acid. 
Stimulation of incorporation of 35S04 into 
GAGs produced by human synovial cells has been 
demonstrated previously with CTAP-111 (5). Partially 
purified CTAP-U at a concentration of 15.4 pgIml 
stimulated 35S04 incorporation into GAG to a modest 
extent (P < 0.01) in synovial cultures. CTAP-111 (12.3 
pg/ml) was a more potent stimulator of 35S04 GAG 
formation than CTAP-U (Figure 4). 
Experiments with human dermal fibroblasts 
showed that CTAP-U stimulated ''C-glucosamine 
incorporation into GAG. Addition of increasing 
amounts of partially purified CTAP-U resulted in 
increasing synthesis of hyaluronic acid (Figurc 5 ) .  At 
concentrations of 60 puglml, maximal stimulation of 
hyaluronate synthesis was noted. Partially purified 
CTAP-U also stimulated 3sS04 incorporation into 
GAG in dermal fibroblasts (E:C ratio 1.4). 
Effect of CTAP-U on proteoglycan monomer 
formation by chondrocytes. Medium from human chon- 
drocytes incubated with 35S04 and fractionated over 
Sepharose 4B showed a radioactive peak in the void 
Q 
10 20 30 40 SO 60 70 120 130 
CTAP-U, p g / m l  
Figure 5.  Dermal fibroblasts show increasing ''C-hyaluronic acid 
(I4C-HA) synthesis in response to increased amounts of partially 
purified connective tissue activating material from urine (CTAP-U). 
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Figure 6. Connective tissue activating material from urine 
(CTAP-Utstimulated human chondrocytes secrete "S-proteogly- 
can, which elutes in the void volume (Vo) of a Sepharose 4B 
column. 
volume. The size of these macromolecules is presum- 
ably greater than 3 million daltons and corresponds 
with the size of protcoglycan (PG) monomer. CTAP-U 
(7 I pg/ml) stimulated increased incorporation of "SO4 
into "S-PG in chondrocyte cultures (Figure 6).  Frac- 
tionation of 3sS-PG from chondrocyte media on Se- 
pharose 2B (data not shown) showed a peak of radio- 
activity in the internal volume of the column, 
indicating that thesc cells form little proteoglycan 
aggregate. These data suggest that CTAP-U is a potent 
stimulator of proteoglycan monomer formation by 
human chondrocytes in vitro. 
Effect of CTAP-U on DNA synthesis. CTAP-U 
stimulated 3H-methylthymidine incorporation into 
DNA in human synovial cells. A dose-response curve 
for partially purified CTAP-U is shown in Figure 7. 
Maximal stimulation of DNA synthesis in synovial 
cells was reached with concentrations of 40 pg/ml of 
CTAP- U . 
Can EGF-URO account for the activity of CTAP- 
U? The possible contamination of CTAP-U by EGF- 
URO was evaluated by a radioreceptor assay with a 
lower limit of sensitivity of 0.4 ng EGF-URO. In the 
RRA for EGF-URO, a small amount of competition 
was observed for fraction Ve, corresponding to a 
maximum of 0.38 ng of EGF-URO for each 1 pg of 
fraction Ve. Further, the negative reaction of 5.3 pg of 
the pH 4.5 CTAP-U fraction in the RRA assay made it 
possible to assign a similar limit for the potential 
content of EGF-URO with this particular CTAP-U 
preparation. 
To ascertain whether the amounts of EGF (0.4 
ng per 1.0 pg CTAP-U) which might contaminate the 
CTAP-U fraction could account for the observed 
biologic activity, mouse EGF (and in one experiment, 
urogastrone) was tested for biologic activity at concen- 
trations similar to those that may have contaminated 
the purified CTAP-U fractions. From the experiments 
shown in Table 3, it was clear that 1-30 pg/ml of 
CTAP-U caused substantial stimulation of GAG syn- 
I I I I I 
0 5 10 15 20 25 
CTAP-U, pg /ml  
Figure 7. Increasing amounts of purified connective tissue activating 
material from urine (CTAP-U) (fraction at pH 4.0) stimulates 
increasing 'H-DNA synthesis. 
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Table 3. Comparison of biologic activity of connective tissue 





Experiment Concen- amino- 
no. Agonist* tration glycan 3H-DNA 
2663 CTAP-U 2 pglml I .4 
8 pg/ml 3.1 
30 pg/ml 9.7 
EGF-I 5 ng/ml 0.8 
50 ng/ml I .0 
2665 CTAP-U 2 pghl 2.5 
EGF-I 200 ng/ml I .4 
40 ng/ml 0.9 
2667 CTAP-U I PkW 3.4 
2 pg/ml 5.9 
30 pglrnl 14.4 
EGF-I 1 ng/ml I .7 
2 ng/ml I .7 
20 ng/ml 4.2 
200 ng/ml 12.3 
2670 CTAP-U 4 pglml 6.4 
EGF-2 5 nglml 2.4 
EGF-3 1 ng/ml 4.0 
2674 CTAP-U 1 pglml 3.9 
2676 CTAP-U 40 pglml 6.9 
EGF-3 50 ng/ml 2. I 
2688 Urogastrone 50 ng/ml 3.0 1.8 
* CTAP-U was a highly purified fraction eluted at pH 4.0 from SP- 
Sephadex; EGF-I, 2, and 3 were mouse EGF obtained from 3 
different sources. 
thesis in human synovial cells. Although with these 
concentrations of CTAP-U one could not, by the 
radioreceptor assay alone, rule out the presence of a 
maximum of 2.4 ng/ml EGF-URO, the simultaneous 
assay of mouse EGF-URO showed that up to 50 ng/ml 
EGF-URO caused little stimulation of HA synthesis in 
synovial cell cultures (Table 3). Thus, EGF-URO, if 
present, could not account for the ability of CTAP-U 
to stimulate I4C-HA synthesis by synovial cells. How- 
ever, the concentration of CTAP-U (fraction at pH 
4.0, 5-10 kg/ml; Figure 7) that caused near maximal 
stimulation of thymidine incorporation might possibly 
have contained sufficient EGF-URO (up to 0.8 ng/ml) 
to account for some of the mitogenic activity of 
CTAP-U. 
DISCUSSION 
The data presented here indicate that human 
urine contains a factor or factors (denoted here collec- 
tively as CTAP-U) that activate human connective 
tissue cells in vitro. The protein fractions isolated from 
urine were able to stimulate glycosaminoglycan syn- 
thesis (both hyaluronate and S04-GAG) in human 
synovial and dermal cell cultures and to stimulate 3H- 
thymidine incorporation in synovial cell cultures. In 
addition, the CTAP-U fractions stimulated ”S04-PG 
formation in human chondrocyte cultures, probably as 
proteoglycan monomer. The CTAP-U activity was 
nondialyzable, sensitive to proteases, and stable in the 
presence of thiols and acid. Most of the biologic 
activity was contained in protein fractions having 
apparent isoelectric points between 4.0 and 4.5. 
An important issue in the present work was to 
determine whether the connective tissue activating 
factor(s) present in human urine might correspond to 
other characterized “growth factors” known to alter 
connective tissue metabolism (26). The growing list of 
such factors includes substances that have been, in 
large part, isolated from blood, blood products, and 
glandular tissue; little is known about the metabolic 
fate and urinary excretion of these substances. 
One growth factor known to be excreted in 
human urine is the well-characterized EGF-urogas- 
trone (isoelectric pH 4 .3 ,  which in normal adults is 
excreted in the urine in amounts ranging from 120- 
1,360 ng/kg/24 hours (27,28). In addition, human urine 
is known to contain components (molecular weights 
28K and 33K) that are much larger than EGF-URO, 
but that cross-react with EGF-URO in radioreceptor 
and radioimmunoassays (29). Although it was not 
possible to exclude unequivocally the presence of a 
small amount (less than 0.001%) of EGF-URO in the 
CTAP-U preparations, the radioreceptor assay dem- 
onstrated clearly that the CTAP-U preparations could 
not have contained sufficient EGF-URO to account for 
the marked stimulation of GAG synthesis in synovial 
cells. 
Our “negative” result with highly purified 
EGF-URO can be contrasted with work with human 
fibroblasts wherein EGF-URO (6 ng/ml, or 10-911.1) has 
been reported to stimulate incorporation of 3H-gluco- 
samine into putative extracellular GAG (30). More- 
over, unlike EGF-URO, which has been reported not 
to stimulate 35S04 incorporation into human fibroblast 
GAG (14), the CTAP-U cleatly did stimulate ”SO4 
incorporation into GAG. Taken together, the data 
indicate that the connective tissue activating activity 
of human urine described here does not represent 
EGF-URO. Likewise, the RRA and RIA analyses 
indicate that the CTAP-U preparations did not contain 
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appreciable amounts of either basic somatomedin (iso- 
electric pH 8.6) or insulin (isoelectric pH 5.30 to  5.35). 
Immunoglobulin G and  some of its components 
have been shown to  stimulate H A  synthesis in synovi- 
al cells (31). A large number of serum proteins are 
detectable in normal urine and, in general, clearances 
of serum proteins tend to  follow their molecular 
weights. IgG is the second most prevalent serum 
protein excreted; Fc and  F a b  fragments of IgG are 
present in lesser concentrations. In this study, urinary 
fractions containing IgG and IgG fragments showed 
stimulation of I4C-GAG synthesis (1.3-2 times control 
values). Urinary IgG and  its fragments probably ac- 
count for some of the biologic activity seen in con- 
centrated urine specimens; however, the stimulatory 
activity of the CTAP-U fractions was clearly indepen- 
dent of IgG. 
The  nature of the connective tissue activating 
material in urine is uncertain. CTAP-U may represent 
an excretory form of members of the CTAP family or 
of other endogenous growth factors; alternatively, it 
may be a substance unique to  the urinary tract. CTAP- 
U differs from CTAP-111, since it did not cross-react 
with CTAP-I11 antibodies; chemical characteristics 
and biologic activities appear to distinguish CTAP-U 
from CTAP-1, which is not mitogenic in synovial cell 
cultures (4). CTAP-U might be  related to  the platelet- 
derived CTAP-P2, since CTAP-P2, like CTAP-U, is 
stable to  heat and  thiols and is able to  stimulate both 
GAG and D N A  synthesis in synovial cell cultures (6). 
Because there are several protein constituents in the 
fractions from human urine that activate connective 
tissue cells, it will be necessary to  obtain each of these 
components in homogeneous form in order to establish 
the relationship of the CTAP-U polypeptide(s) to other 
known growth factors. 
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